Enrico Balducci

Dr. Enrico Balducci

School of Biosciences and Medicine Veterinary, University of Camerino, 62032 Camerino (MC), Italy

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2012 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
EMEnrico Malito
Enrico Malito
BBBadry Bursulaya
Badry Bursulaya
CCConnie Chen
Connie Chen
PSPaola Lo Surdo
Paola Lo Surdo
MPMonica Picchianti
Monica Picchianti
GSGlen Spraggon
Glen Spraggon
CRM197 is an enzymatically inactive and nontoxic form of diphtheria toxin that contains a single amino acid substitution (G52E). Being naturally nontoxic, CRM197 is an ideal carrier protein for conjugate vaccines against encapsulated bacteria and is currently used to vaccinate children globally against Haemophilus influenzae , pneumococcus, and meningococcus. To understand the molecular basis for lack of toxicity in CRM197, we determined the crystal structures of the full-length nucleotide-free CRM197 and of CRM197 in complex with the NAD hydrolysis product nicotinamide (NCA), both at 2.0-Å resolution. The structures show for the first time that the overall fold of CRM197 and DT are nearly identical and that the striking functional difference between the two proteins can be explained by a flexible active-site loop that covers the NAD binding pocket. We present the molecular basis for the increased flexibility of the active-site loop in CRM197 as unveiled by molecular dynamics simulations. These structural insights, combined with surface plasmon resonance, NAD hydrolysis, and differential scanning fluorimetry data, contribute to a comprehensive characterization of the vaccine carrier protein, CRM197.

1 June 1995 in Analytical Biochemistry
Verified
Journal Article
Closed access
Enrico BalducciEnrico Balducci
Enrico Balducci
MEM. Emanuelli
M. Emanuelli
NRN. Raffaelli
N. Raffaelli
SRS. Ruggieri
S. Ruggieri
AAAdolfo Amici
Adolfo Amici
PNP. Natalini
P. Natalini

4 November 2015 in Biochemistry
Verified
Journal Article
Closed access
ABAlessio Bonucci
Alessio Bonucci
ECElena Caldaroni
Elena Caldaroni
Enrico BalducciEnrico Balducci
Enrico Balducci
Rebecca PogniRebecca Pogni
Rebecca Pogni

9 October 2003 in Molecular Microbiology
Verified
Journal Article
Open access
PDF file
VMVega Masignani
Vega Masignani
Enrico BalducciEnrico Balducci
Enrico Balducci
FMFederica Di Marcello
Federica Di Marcello
SSSilvana Savino
Silvana Savino
DSDavide Serruto
Davide Serruto
JAJeannette Adu-Bobie
Jeannette Adu-Bobie
Mono ADP-ribosyltransferases (ADPRTs) are a class of functionally conserved enzymes present in prokaryotic and eukaryotic organisms. In bacteria, these enzymes often act as potent toxins and play an important role in pathogenesis. Here we report a profile-based computational approach that, assisted by secondary structure predictions, has allowed the identification of a previously undiscovered ADP-ribosyltransferase in Neisseria meningitidis (NarE). NarE shows structural homologies with E. coli heat-labile enterotoxin (LT) and cholera toxin (CT) and possesses ADP-ribosylating and NAD-glycohydrolase activities. As in the case of LT and CT, NarE catalyses the transfer of the ADP-ribose moiety to arginine residues. Despite the absence of a signal peptide, the protein is efficiently exported into the periplasm of Neisseria. The narE gene is present in 25 out of 43 strains analysed, is always present in ET-5 and Lineage 3 but absent in ET-37 and Cluster A4 hypervirulent lineages. When present, the gene is 100% conserved in sequence and is inserted upstream of and co-transcribed with the lipoamide dehydrogenase E3 gene. Possible roles in the pathogenesis of N. meningitidis are discussed.

1 July 2016 in Vaccine
Verified
Journal Article
Open access
MTM. Tontini
M. Tontini
MRM.R. Romano
M.R. Romano
DPD. Proietti
D. Proietti
Enrico BalducciEnrico Balducci
Enrico Balducci
FMF. Micoli
F. Micoli
PCPaolo Costantino
Paolo Costantino
Glycoconjugate vaccines are made of carbohydrate antigens covalently bound to a carrier protein to enhance their immunogenicity. Among the different carrier proteins tested in preclinical and clinical studies, five have been used so far for licensed vaccines: Diphtheria and Tetanus toxoids, the non-toxic mutant of diphtheria toxin CRM197, the outer membrane protein complex of Neisseria meningitidis serogroup B and the Protein D derived from non-typeable Haemophilus influenzae. Availability of novel carriers might help to overcome immune interference in multi-valent vaccines containing several polysaccharide-conjugate antigens, and also to develop vaccines which target both protein as well saccharide epitopes of the same pathogen. Accordingly we have conducted a study to identify new potential carrier proteins. Twenty-eight proteins, derived from different bacteria, were conjugated to the model polysaccharide Laminarin and tested in mice for their ability in inducing antibodies against the carbohydrate antigen and eight of them were subsequently tested as carrier for serogroup meningococcal C oligosaccharides. Four out of these eight were able to elicit in mice satisfactory anti meningococcal serogroup C titers. Based on immunological evaluation, the Streptococcus pneumoniae protein spr96/2021 was successfully evaluated as carrier for serogroups A, C, W, Y and X meningococcal capsular saccharides.

1 February 2013 in Biochimica et Biophysica Acta (BBA) - Biomembranes
Verified
Journal Article
Closed access
ABAlessio Bonucci
Alessio Bonucci
Enrico BalducciEnrico Balducci
Enrico Balducci
SPSara Pistolesi
Sara Pistolesi
RPRebecca Pogni
Rebecca Pogni